Randomized, Double-Blind, Comparative Study to Evaluate the Safety and Efficacy of ZTI-01 vs Piperacillin/Tazobactam in the Treatment of cUTI/AP Infection in Hospitalized Adults

Trial Profile

Randomized, Double-Blind, Comparative Study to Evaluate the Safety and Efficacy of ZTI-01 vs Piperacillin/Tazobactam in the Treatment of cUTI/AP Infection in Hospitalized Adults

Completed
Phase of Trial: Phase II/III

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs Fosfomycin (Primary) ; Piperacillin/tazobactam
  • Indications Pyelonephritis; Urinary tract infections
  • Focus Registrational; Therapeutic Use
  • Acronyms ZEUS
  • Sponsors Zavante Therapeutics
  • Most Recent Events

    • 04 Oct 2017 Results of a post-hoc analysis published in the Zavante Therapeutics Media Release
    • 20 Sep 2017 According to a Zavante Therapeutics media release, data will be presented at ID Week 2017.
    • 08 Sep 2017 According to a Zavante Therapeutics media release, the company plans to submit NDA for fosfomycin for injection to the US FDA in early 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top